title: Successful crizotinib rechallenge after crizotinib-induced organizing pneumonia in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.
abstract: Crizotinib, a first-line anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor, has shown promising results for the treatment of locally advanced and metastatic lung cancer presenting the ALK rearrangement. On the other hand, secondary organizing pneumonia (OP) caused by anti-cancer drugs has been reported. While it is sometimes needed to rechallenge the suspected drug, the standard therapeutic strategy for secondary OP has not yet been established. We report a 60-year-old male with ALK-rearranged non-small cell lung cancer who developed crizotinib-induced OP and was successfully rechallenged with crizotinib. Six months after the rechallenge, the patient has achieved a partial response. To our knowledge, this is the first case in which crizotinib-induced OP has been successfully treated.
authors.affiliation: Divisions of Respiratory Medicine and Allergology, Aichi Medical University School of Medicine, Nagakute, Japan.
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Asai
authors.affiliation: Divisions of Pathology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
authors.forename: Toyoharu
authors.initials: T
authors.lastname: Yokoi
authors.affiliation: Divisions of Respiratory Medicine and Allergology, Aichi Medical University School of Medicine, Nagakute, Japan.
authors.forename: Etsuro
authors.initials: E
authors.lastname: Yamaguchi
authors.affiliation: Divisions of Respiratory Medicine and Allergology, Aichi Medical University School of Medicine, Nagakute, Japan.
authors.forename: Akihito
authors.initials: A
authors.lastname: Kubo
keywords: Crizotinib; EML4-ALK; Lung cancer; Organizing pneumonia